Metabotropic Glutamate Receptor 7, Pipeline Review, H2 2019 - Addex Therapeutics, Aevi Genomic Medecine Inc & Bio-Pharm Solutions Co Ltd - ResearchAndMarkets.com

DUBLIN--()--The "Metabotropic Glutamate Receptor 7 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 7 - Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), Alzheimer's Disease, Epilepsy, Infantile Spasm (West Syndrome), Opium (Opioid) Addiction, Rett Syndrome, Status Epilepticus and Visceral Pain.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
  • The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Overview
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bio-Pharm Solutions Co Ltd
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Drug Profiles
  • ADX-71743 - Drug Profile
  • AEVI-004 - Drug Profile
  • JBPOS-0101 - Drug Profile
  • LSP-29166 - Drug Profile
  • Small Molecule to Agonize mGlu7 for Rett Syndrome - Drug Profile
  • Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Dormant Products
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Discontinued Products
  • Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cfi4sl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900